IE
ADMS

Israel Englander’s Adamas Pharmaceuticals ADMS Stock Holding History

Israel Englander’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-146,750
Closed -$704K – 7388
2021
Q1 		$704K Buy
+146,750
New +$766K ﹤0.01% 4535
2019
Q3 		– Sell
-325,417
Closed -$2.02M – 4704
2019
Q2 		$2.02M Sell
325,417
-692,566
-68% -$3.98M ﹤0.01% 2397
2019
Q1 		$7.24M Buy
1,017,983
+538,084
+112% +$4.84M 0.01% 1508
2018
Q4 		$4.1M Buy
479,899
+229,404
+92% +$2.98M 0.01% 1722
2018
Q3 		$5.01M Sell
250,495
-91,685
-27% -$2.15M 0.01% 1796
2018
Q2 		$8.84M Buy
342,180
+260,360
+318% +$7.21M 0.01% 1406
2018
Q1 		$1.96M Sell
81,820
-575,263
-88% -$18.1M ﹤0.01% 2336
2017
Q4 		$22.3M Sell
657,083
-603,496
-48% -$16.9M 0.03% 840
2017
Q3 		$26.7M Buy
1,260,579
+923,203
+274% +$16.9M 0.04% 633
2017
Q2 		$5.9M Sell
337,376
-105,691
-24% -$1.75M 0.01% 1403
2017
Q1 		$7.75M Sell
443,067
-96,782
-18% -$1.65M 0.01% 1176
2016
Q4 		$9.12M Sell
539,849
-177,526
-25% -$2.75M 0.02% 981
2016
Q3 		$11.8M Buy
717,375
+160,806
+29% +$2.44M 0.02% 839
2016
Q2 		$8.43M Buy
556,569
+542,577
+3,878% +$8.95M 0.02% 957
2016
Q1 		$202K Sell
13,992
-359,248
-96% -$6.05M ﹤0.01% 2952
2015
Q4 		$10.6M Buy
373,240
+319,689
+597% +$5.38M 0.02% 900
2015
Q3 		$896K Buy
53,551
+35,883
+203% +$816K ﹤0.01% 2348
2015
Q2 		$463K Sell
17,668
-27,087
-61% -$527K ﹤0.01% 2672
2015
Q1 		$783K Buy
44,755
+32,500
+265% +$557K ﹤0.01% 2463
2014
Q4 		$213K Buy
+12,255
New +$186K ﹤0.01% 3592

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Israel Englander's ADMS Position: Q2 2021 in Review

Israel Englander sold out of Adamas Pharmaceuticals (ADMS) in Q2 2021, closing a stake of 146,750 shares — an estimated $704K sold.

Israel Englander first reported a position in ADMS in Q4 2014 and held it in 20 quarters. The position peaked at $26.7M in Q3 2017. 67 funds tracked by Wall St. Rank hold ADMS as of Q2 2021.

  • Israel Englander reported no remaining Adamas Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Israel Englander sold 146,750 Adamas Pharmaceuticals shares in Q2 2021, an estimated $704K.
  • Israel Englander first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 20 quarters.
  • Israel Englander's Adamas Pharmaceuticals position peaked at $26.7M in Q3 2017.
  • 67 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2021.

Based on Millennium Management's 13F filing for Q2 2021, filed 16 Aug 2021.